Skip to contentB
BioMarin Pharmaceutical Inc
B
BMRNBioMarin Pharmaceutical Inc Q4 2020 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$452.12M$452.12Mderived−0.5% vs Q4 2019 Net Income$17.03M$17.03Mderived+13.3% vs Q4 2019 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BioMarin Pharmaceutical Inc · CIK 1048477 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$51,515,000N/M Operating Cash Flowderived-$13,384,000N/M Free Cash Flowderived-$44,410,000N/M Margins · derivedOperating margin-11.4%−9.4 pt vs Q4 2019
Net margin3.8%+0.5 pt vs Q4 2019
ended Dec 31, 2020 · filed Feb 26, 2021 · 57 d after period end